Abstract
The high frequency of MBL2 mutant alleles found in various human populations suggests that they provide some selective advantage. One of the hypotheses is that MBL deficiency may be protective against intracellular pathogens, including Mycobacterium leprae. In this study, we investigated the role of MBL2 in the susceptibility to leprosy. Single-nucleotide variants (SNV) B (rs1800450) and C (rs1800451) in exon 1 of the MBL2 gene and serum MBL concentrations were assessed in 53 patients with leprosy and 68 healthy controls from southeast Brazil by polymerase chain reaction followed by restriction fragment length polymorphism and commercial capture enzyme-linked immunosorbent assay, respectively. The genotyped SNVs were significantly associated with increased protection against leprosy (OR=0.3757, 95% CI=0.1615⍰08740, p=0.0273) and more severe forms, including multibacillary (OR=0.3769, 95% CI=0.1447⍰0.9818, p=0.0493) and lepromatous (OR=0.2423, 95% CI=0.06547⍰0.8968, p=0.0369) leprosy. On the other hand, low-MBL producing genotypes were associated with the protection for leprosy, especially in its more severe forms. Low MBL levels and low MBL producing variants were associated with protection against leprosy and progression to more severe forms of this disease. Moreover, this study highlights MBL as a regulator of immune function in which alterations may affect normal responses to leprosy infection and inflammatory stimuli.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has been supported by Foundation Carlos Chagas Filho Research Support of the State of Rio de Janeiro (FAPERJ) - APQ-1 E-26/111.196/2014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Regional Ethics Committee of the Faculdade de Medicina de Campos under CAEE no. 19679119.8.0000.5244. All study participants were informed about the research and signed a term of informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Thereza L. Kipnis2: In memoriam: Her recognized visionary academic in M. leprae initiatives stimulated the integration of UENF and its social surroundings.
Data Availability
The dataset supporting the findings of this article is available from the corresponding author upon request.
Abreviations
- MBL
- mannose binding-lectin
- SNV
- single nucleotide variant
- PCR-RFLP
- polymerase chain reaction-restriction fragment length polymorphism
- MBP-oligomer
- oligomeric MBL carbohydrate-binding domain
- ELISA
- enzyme linked immunosorbent assay
- OR
- odd ratio
- CI
- confidence interval
- M. leprae
- Mycobacterium leprae
- WHO
- world health organization
- L
- leprosy patients
- HC
- healthy controls
- MB
- multibacillary patients
- PB
- paucibacillary patients
- LL
- lepromatous leprosy
- DL
- dimorph leprosy
- IDL
- indeterminate leprosy
- TL
- tuberculoid leprosy
- TMB
- tetramethylbenzidine
- DNA
- deoxyribonucleic acid.